Using DNA as a drug - bioprocessing and delivery strategies

Han, Ying, Liu, Shan, Ho, Jenny, Danquah, Michael K., & Forde, Gareth M. (2009) Using DNA as a drug - bioprocessing and delivery strategies. Chemical Engineering Research and Design, 87(3), pp. 343-348.

View at publisher


DNA may take a leading role in a future generation of blockbuster therapeutics. DNA has inherent advantages over other biomolecules such as protein, RNA and virus-like particles including safety, production simplicity and higher stability at ambient temperatures. Vaccination is the principal measure for preventing influenza and reducing the impact of pandemics; however, vaccines take up to 8-9 months to produce, and the global production capacity is woefully low. With production times as short as 2 weeks, improved safety and stability, bioprocess engineering developments, and the ability to perform numerous therapeutic roles, DNA has the potential to meet the demands of emerging and existing diseases. DNA is experiencing sharp growths in demand as indicated by its use in gene therapy trials and DNA vaccine related patents. Of particular interest for therapeutic use is plasmid DNA (pDNA), a form of non-genomic DNA that makes use of cellular machinery to express proteins or antigens. The production stages of fermentation and downstream purification are considered in this article. Forward looking approaches to purifying and delivering DNA are reported, including affinity chromatography and nasal inhalation. The place that pDNA may take in the preparation for and protection against pandemics is considered. If DNA therapeutics and vaccines prove to be effective, the ultimate scale of production will be huge which shall require associated bioprocess engineering research and development for purification of this large, unique biomolecule.

Impact and interest:

13 citations in Scopus
Search Google Scholar™
10 citations in Web of Science®

Citation counts are sourced monthly from Scopus and Web of Science® citation databases.

These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.

Citations counts from the Google Scholar™ indexing service can be viewed at the linked Google Scholar™ search.

ID Code: 81540
Item Type: Journal Article
Refereed: Yes
Keywords: Bioprocess engineering, DNA therapeutics, Pandemic preparedness, Plasmid DNA, Affinity chromatography, Biochemical engineering, Biomolecules, Chromatographic analysis, DNA, Engineering research, Genes, Genetic engineering, Ligands, Machinery, Organic acids, Purification, Quality assurance, RNA, Safety engineering, Vaccines, Ambient temperatures, Bioprocessing, Cellular machineries, Dna vaccines, Forward looking, Future generations, Gene therapies, Global productions, Production stages, Scale of productions, Therapeutic use, Virus-like particles, Nucleic acids
DOI: 10.1016/j.cherd.2008.09.010
ISSN: 0263-8762
Divisions: Current > Schools > School of Chemistry, Physics & Mechanical Engineering
Current > QUT Faculties and Divisions > Science & Engineering Faculty
Copyright Owner: Copyright 2008 The Institution of Chemical Engineers
Deposited On: 05 Feb 2015 23:44
Last Modified: 11 Feb 2015 03:07

Export: EndNote | Dublin Core | BibTeX

Repository Staff Only: item control page